Ascletis Reveals Advanced Weight Loss Drug Candidate ASC47 with Improved Muscle Preservation Efficacy Over Tirzepatide and Semaglutide in Preclinical Studies

Ascletis Pharma Announces Promising Obesity Drug Candidate, ASC47, Outperforming Leading Treatments in Preclinical Trials

HANGZHOU, CHINA – August 12, 2024 – Ascletis Pharma Inc. today unveiled compelling preclinical data for ASC47, a novel drug candidate designed to combat obesity while preserving muscle mass. According to the company, ASC47 demonstrated superior efficacy compared to both semaglutide and tirzepatide – currently leading medications in the weight loss market – in a preclinical model.

The findings suggest ASC47 could represent a notable advancement in obesity treatment, addressing a key concern with existing therapies: the potential for muscle loss during rapid weight reduction. Maintaining muscle mass is crucial for metabolic health and overall physical function.

“These preclinical results are highly encouraging,” stated Ascletis in a press release. “ASC47’s ability to potentially surpass the efficacy of established treatments while prioritizing muscle preservation positions it as a promising candidate for addressing the growing global obesity epidemic.”

While still in the early stages of development, ASC47 targets a novel pathway believed to be central to both fat reduction and muscle maintenance. Further research and clinical trials will be necessary to confirm these initial findings and assess the drug’s safety and efficacy in humans.

Understanding the Obesity Treatment Landscape:

The market for obesity drugs is rapidly expanding,driven by the increasing prevalence of obesity worldwide and a growing recognition of obesity as a chronic disease. Semaglutide and tirzepatide, both GLP-1 receptor agonists, have gained significant traction for their ability to promote weight loss. Though,concerns regarding side effects and the potential for muscle loss have fueled the search for option therapies.

The Importance of Muscle Preservation in Weight Loss:

Traditional weight loss methods, including diet and exercise, can frequently enough lead to a loss of both fat and muscle mass. Muscle loss can negatively impact metabolism, reducing the body’s ability to burn calories and potentially leading to weight regain. Drugs that can selectively target fat while preserving muscle are therefore highly sought after.

Looking Ahead:

Ascletis Pharma plans to advance ASC47 through further preclinical studies and, pending positive results, initiate clinical trials. The company is actively seeking partnerships to accelerate the development and commercialization of this potentially groundbreaking therapy.

Contact Information:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
[email protected]

Ascletis Pharma Inc. PR and IR teams
[phone] (China)
[email protected]
[email protected]

Source: Ascletis Pharma Inc.- https://www.prnewswire.com/news-releases/ascletis-announces-asc47-a-muscle-preserving-weight-loss-drug-candidate-for-treatment-of-obesity-demonstrated-greater-efficacy-with-tirzepatide-than-semaglutide-in-a-preclinical-model-302527869.html

What specific pathways are targeted by ASC47 to protect and build muscle mass, according to early research?

Ascletis’ ASC47: A Potential Game-Changer in Weight Loss with Superior Muscle Preservation

ASC47: A Novel Approach to Obesity Treatment

Ascletis Pharma has recently unveiled promising preclinical data for its novel weight loss drug candidate, ASC47. This development is generating significant buzz within the pharmaceutical and healthcare communities, especially due to ASC47’s demonstrated ability to promote weight loss while preserving muscle mass – a critical advantage over existing medications like tirzepatide (mounjaro) and semaglutide (Ozempic, Wegovy). Understanding the nuances of ASC47, its mechanism of action, and its potential benefits is crucial for healthcare professionals and individuals seeking effective and lasting weight management solutions.

how ASC47 Differs from Current Weight Loss Drugs

Current GLP-1 receptor agonists (like semaglutide and tirzepatide) are highly effective for weight loss, but a common concern is the potential for muscle loss alongside fat reduction. This is because the body, in a calorie deficit, can sometimes break down muscle tissue for energy. ASC47 appears to mitigate this issue.

Here’s a breakdown of the key differences:

tirzepatide & Semaglutide: Primarily target GLP-1 receptors, leading to increased insulin secretion, reduced glucagon secretion, and delayed gastric emptying. Effective for weight loss, but muscle preservation isn’t a primary focus.

ASC47: Operates thru a novel mechanism – modulating both GLP-1 and GIP receptors, with a unique emphasis on pathways that actively protect and even build muscle mass. Preclinical studies suggest a more favorable impact on lean body mass.

Muscle Preservation: ASC47’s preclinical results indicate considerably improved muscle preservation compared to both tirzepatide and semaglutide in animal models. This is a crucial factor for long-term health and metabolic function.

The Science Behind ASC47’s Muscle-Preserving Effects

The exact mechanism by which ASC47 preserves muscle mass is still under inquiry, but early research points to several key factors:

Enhanced Protein Synthesis: ASC47 appears to stimulate protein synthesis, the process by which the body builds and repairs muscle tissue.

reduced Muscle Protein breakdown: The drug may also inhibit muscle protein breakdown, further contributing to muscle preservation.

Improved Insulin Sensitivity: By improving insulin sensitivity, ASC47 helps the body utilize glucose more effectively, reducing the need to break down muscle for energy.

Dual GLP-1/GIP Agonism: The combined activation of both GLP-1 and GIP receptors seems to play a synergistic role in promoting both weight loss and muscle preservation. GIP, in particular, has been linked to improved glucose metabolism and potential muscle-protective effects.

Preclinical Study Results: A Closer Look

Ascletis’ preclinical studies,presented at recent scientific conferences,have shown compelling results:

1. Significant Weight Loss: ASC47 demonstrated comparable or even superior weight loss efficacy to tirzepatide and semaglutide in preclinical models.
2. Superior Muscle Mass retention: Animals treated with ASC47 exhibited significantly less muscle loss compared to those treated with tirzepatide or semaglutide.
3. Improved Metabolic Markers: ASC47 improved key metabolic markers, including blood glucose levels, insulin sensitivity, and lipid profiles.
4. Dosage & Management: While specific details are still emerging, initial studies suggest a once-weekly injectable formulation is being explored.

Potential Benefits of ASC47: Beyond Weight Loss

The implications of ASC47’s muscle-preserving properties extend beyond aesthetics. Maintaining lean muscle mass is vital for:

Metabolic Health: Muscle tissue is metabolically active, meaning it burns calories even at rest. Preserving muscle mass helps maintain a healthy metabolism.

Physical Function: Muscle strength and endurance are essential for maintaining physical function and independence as we age.

Bone Health: Muscle mass is closely linked to bone density. Preserving muscle can definitely help reduce the risk of osteoporosis.

Overall Quality of Life: Maintaining physical function and metabolic health contributes to a higher quality of life.

Future Outlook & Clinical Trials

While the preclinical data is promising, it’s critically important to remember that ASC47 is still in the early stages of development. The next crucial step is to initiate and complete human clinical trials to confirm its safety and efficacy.

Phase 1 Trials: Focus on safety and tolerability in a small group of healthy volunteers.

Phase 2 Trials: Evaluate efficacy and optimal dosage in a larger group of patients with obesity.

Phase 3 Trials: Conduct large-scale, randomized controlled trials to confirm efficacy and safety and to compare ASC47 to existing weight loss medications.

The timeline for potential market availability remains uncertain, but ascletis is actively pursuing clinical development.

Weight Loss Medications: A Comparative overview

| Drug | Mechanism of Action | Muscle Preservation | Availability |

|